JMJD6 and breast carcinoma: Survival analysis of breast cancer patients up to 4 years (about 1500 days) showed poorer prognosis when expression of both JMJD6 and EZH2 was high, however it did not achieve statistical significance by the end of 5 years (Additional file 7).